Literature DB >> 1805938

Antibody labeling with copper-67 using the bifunctional macrocycle 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)methyl]benzoic acid.

P M Smith-Jones1, R Fridrich, T A Kaden, I Novak-Hofer, K Siebold, D Tschudin, H R Maecke.   

Abstract

The high kinetic stability of the Cu2+ complex of the chelator 4-[(1,4,8,11-tetraazacyclotetradec-1-yl)-methyl]benzoic acid was demonstrated at physiological pH as well as under acidic conditions. The chelating agent was conjugated to AB35, a monoclonal antibody directed against CEA, without a significant loss of immunoreactivity. The conjugate could, under optimal labeling conditions, be labeled with 67Cu in acetate buffer with a full occupancy of ligands within 20 min. This radiolabeled conjugate showed no transfer of radiocopper to serum proteins in human serum over 7 days. The biodistribution in tumor-bearing mice was measured and compared to that of iodinated AB35. Tumor uptake was high with 15 +/- 3% ID (injected dose)/g after 24 h and 32 +/- 7% ID/g after 96 h for the 67Cu-labeled antibody and 13 +/- 4% ID/g after 24 h and 14 +/- 2% ID/g after 96 h for the 125I-labeled antibody. Whereas radioactivity in normal organs decreased with time after 24 h, increased residence time was shown up to 4 days with the 67Cu-labeled AB35.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1805938     DOI: 10.1021/bc00012a006

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  7 in total

1.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

2.  A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Authors:  Brian M Zeglis; Jason S Lewis
Journal:  Dalton Trans       Date:  2011-03-25       Impact factor: 4.390

3.  Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography.

Authors:  Sridhar Nimmagadda; Mrudula Pullambhatla; Kristie Stone; Gilbert Green; Zaver M Bhujwalla; Martin G Pomper
Journal:  Cancer Res       Date:  2010-05-11       Impact factor: 12.701

4.  H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.

Authors:  Eric W Price; Brian M Zeglis; Jason S Lewis; Michael J Adam; Chris Orvig
Journal:  Dalton Trans       Date:  2014-01-07       Impact factor: 4.390

Review 5.  New magnetic resonance imaging techniques for the detection of breast cancer.

Authors:  K Orang-Khadivi; B L Pierce; C M Ollom; L J Floyd; R L Siegle; R F Williams
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  Evolution of bombesin conjugates for targeted PET imaging of tumors.

Authors:  Hanwen Zhang; Keelara Abiraj; Daniel L J Thorek; Beatrice Waser; Peter M Smith-Jones; Michael Honer; Jean Claude Reubi; Helmut R Maecke
Journal:  PLoS One       Date:  2012-09-14       Impact factor: 3.240

7.  Photoactivatable bis(thiosemicarbazone) derivatives for copper-64 radiotracer synthesis.

Authors:  Daniel F Earley; Jose Esteban Flores; Amaury Guillou; Jason P Holland
Journal:  Dalton Trans       Date:  2022-03-29       Impact factor: 4.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.